Patent · US Active

Method for evaluating the response of an individual to a treatment with a type I interferon (IFN)

US8426170B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignee

UNIVERSITÉ LIBRE DE BRUXELLES · BE

Inventors

Patrick Stordeur · Brussels, BE
Mathieu Vokaer · Sint-Genesius-Rode, BE
Annick Ocmant · Mons, BE
Michel Goldman · Brussels, BE

Key dates

Filing date	Jan 24, 2008
Grant date	Apr 23, 2013
Priority date	—
Expiry date	Nov 29, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably MxA, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.